Q-omics provides the consensus-scored HOXD1 profile across patient tissues and cancer cell-line models. HOXD1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, HOXD1 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, HOXD1 RNA expression shows 16,514 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRP, KIRC, and THYM as cancer lineages where HOXD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HOXD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HOXD1 survival associations across molecular data types. HOXD1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HOXD1 RNA expression–survival associations across cancer types. High HOXD1 expression shows unfavorable associations in KIRP, MESO, ACC, UCEC and COAD, but favorable associations in KIRC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for HOXD1 RNA expression.
This table summarizes HOXD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for HOXD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HOXD1 shows lower tumor expression in KIRC, KICH, COAD and LUSC and higher tumor expression in HNSC and THCA. The KIRC box plot shows higher HOXD1 RNA expression in normal versus tumor tissue (log2 FC = −0.960, t-test p < 0.001).
This table shows molecular features associated with HOXD1 in patient tissues and cancer cell lines. In patient samples, HOXD1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, HOXD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BONE.
